In addition, in hepatocarcinoma, the increased levels of LDLR have been associated with the downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a new pivotal pharmacological target for controlling hypercholesterolemia [33]. Here, PCSK9 is linked to familial hypercholesterolemia.